Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Idiopathic Inflammatory Myopathies: early-phase trial registry
5 of 8 indexed Idiopathic Inflammatory Myopathies trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,176 of 28,707 conditions by registered trial count.
8 US clinical trials · 5 currently recruiting · #2,176 of 28,707 conditions by registered trial count
Idiopathic Inflammatory Myopathies: 8 US clinical trials tracked, 5 recruiting.
Idiopathic Inflammatory Myopathies is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is AstraZeneca, running 2 of these trials.
Enrollment posture brief
Registry condition idiopathic-inflammatory-myopathies
OPEN 5 | RECR 63% | LATE 0 | EARLY 7 | RANK #2176 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Adolescent (63% recruiting · 16 trials)
Idiopathic Inflammatory Myopathies lists 5 open slots (63% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Idiopathic Inflammatory Myopathies on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Idiopathic Inflammatory Myopathies is recruiting above its size-band peers.
5 of 8 indexed trials (62.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Idiopathic Inflammatory Myopathies research.
AstraZeneca accounts for 2 of 8 trials (25%). 7 distinct sponsors appear on at least one study for this condition label.
-
Most Idiopathic Inflammatory Myopathies trials plan to enrol fewer than 100 people.
Median target enrolment is 72 among the 8 trials that report a genuine target (sentinel values excluded). 5 of those (62.5%) plan for fewer than 100 participants.
-
Idiopathic Inflammatory Myopathies research is mostly interventional.
7 interventional and 1 observational studies make up this index (87.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
8 total, page 1 of 1
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
Nkarta
NCT06733935
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
Novartis Pharmaceuticals
NCT06665256
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
AstraZeneca
NCT06916806
A Study of AZD0120 in Autoimmune Diseases
AstraZeneca
NCT07295847
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis
Austin Neuromuscular Center
NCT06479863
CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101
David Porter
NCT06152172
A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
Century Therapeutics
NCT06255028
Study of Families With Twins or Siblings Discordant for Rheumatic Disorders
National Institute of Environmental Health Sciences (NIEHS)
NCT00055055
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Idiopathic Inflammatory Myopathies records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Idiopathic Inflammatory Myopathies trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Idiopathic Inflammatory Myopathies page
8 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Idiopathic Inflammatory Myopathies trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- AstraZeneca sponsors the most Idiopathic Inflammatory Myopathies trials on record, review their full trial history before evaluating a specific study. See AstraZeneca's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Idiopathic Inflammatory Myopathies condition card totals 8 registered trials; most-linked intervention Fludarabine; top US site state Illinois. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.